Catumaxomab

Catumaxomab
Monoclonal antibody
TypeTrifunctional antibody
SourceRat/mouse hybrid
TargetEpCAM, CD3
Clinical data
Trade namesRemovab, others
AHFS/Drugs.comInternational Drug Names
Routes of
administration
intraperitoneal infusion
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Catumaxomab,[1] sold under the brand name Removab among others, is a rat-mouse hybrid monoclonal antibody which is used to treat malignant ascites, a condition occurring in people with metastasizing cancer. It binds to antigens CD3 and EpCAM. It was developed by Fresenius Biotech and Trion Pharma (Germany).

  1. ^ Linke R, Klein A, Seimetz D (2010). "Catumaxomab: clinical development and future directions". mAbs. 2 (2): 129–36. doi:10.4161/mabs.2.2.11221. PMC 2840231. PMID 20190561.